At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,028 enrolled
Drug / intervention
cabozantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
In Brief
A Phase 3 clinical trial evaluating cabozantinib and prednisone for Prostate Cancer and 3 related conditions. Completed, enrolled 1,028 participants across 264 sites in 14 countries.
Detailed Summary
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionSep 2014
Study CompletionMar 2015
TodayJul 2026
First PostedMay 24, 2012
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.1 years ago
Interventions
cabozantinibdrug
Tablets taken orally once-daily
prednisonedrug
Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.